Thermo Fisher Scientific (TMO) Q3 2026: Revenue and EPS Growth — Strong Performance: Slides 3.2% at Open — Post-Earnings Analysis

Thermo Fisher Scientific Inc. (NYSE: TMO) reported a robust third quarter for 2026, with revenue increasing by $1.02 billion or +9% year-over-year, reaching $12.14 billion compared to $11.12 billion in Q3 2025. This growth was complemented by a 9% increase in GAAP diluted earnings per share (EPS), which rose to $4.64, and a 15% increase in adjusted EPS, which reached $6.68.

This quarter's performance is a positive outcome for shareholders, reflecting the effectiveness of Thermo Fisher's growth strategy and operational execution. The company’s ability to deliver consistent revenue and earnings growth demonstrates its resilience and adaptability in a competitive market.

Key Financial Metrics

• Revenue: $12.14 billion, up $1.02 billion or +9% YoY
• GAAP Diluted EPS: $4.64, up 9% YoY
• Adjusted EPS: $6.68, up 15% YoY
• Organic Revenue Growth: 6%
• GAAP Operating Income: $2.26 billion, up 17% YoY
• GAAP Operating Margin: 18.6%, compared to 17.4% in Q3 2025
• Adjusted Operating Income: $2.97 billion, up 15% YoY
• Adjusted Operating Margin: 24.5%, compared to 23.3% in Q3 2025
• Free Cash Flow: $2.11 billion, up from $1.84 billion YoY

Dividend and Share Buyback

Thermo Fisher continues to prioritize shareholder returns, having paid dividends totaling $511 million during the quarter. Additionally, the company executed share repurchases amounting to $4 billion, reflecting its commitment to returning capital to shareholders.

Guidance Update

During the earnings conference call, Thermo Fisher indicated that it would provide updated financial guidance for 2026. Investors should pay close attention to this guidance, as it will offer insights into the company's expectations for future performance and strategic initiatives.

Forward Catalysts

Looking ahead, investors should watch for the continued execution of Thermo Fisher's growth strategy, particularly the launch of innovative products and expansion into new markets. The company’s recent initiatives, such as the opening of an AI-Automation Innovation Center in South Korea and partnerships like the one with Mayo Clinic, are expected to drive future growth and enhance its competitive position in the life sciences sector.

In summary, Thermo Fisher Scientific's Q3 2026 results reflect a strong operational performance, with significant revenue and earnings growth. The company's strategic initiatives and commitment to shareholder returns position it well for continued success in the upcoming quarters.

Note: All amounts in the following tables are in millions.

Quarterly Earnings — Revenue vs. Estimate

Revenue vs. Estimate — 5 Quarters

EPS vs. Estimate — 5 Quarters

Analyst Ratings & Price Targets

Wall Street analysts have recently displayed mixed sentiment toward Thermo Fisher Scientific Inc. (TMO), with notable rating changes influencing the stock’s outlook. UBS upgraded TMO from Neutral to Buy on September 9, setting a $730 price target, while CLSA initiated coverage on September 3 with an Outperform rating and a $748 target. Earlier in June, Bernstein resumed coverage at Market Perform ($520), Piper Sandler initiated with Neutral ($510), and HSBC downgraded the stock from Buy to Hold ($540). Wolfe Research also resumed coverage with an Outperform rating ($535). The consensus price target currently implies moderate upside from TMO’s recent trading levels, though analyst views remain divided. The spread between targets—from $510 to $748—reflects differing expectations for growth and valuation, leaving investors to weigh the potential upside against lingering caution from some firms.

Technical Analysis — 90-Day Price Chart

Thermo Fisher Scientific Inc. (TMO) trades at $694.02, maintaining a bullish posture above key moving averages: the SMA20 ($672.25), SMA50 ($641.72), and SMA200 ($589.15), reinforcing an uptrend. The SMA20’s recent crossover above the SMA50 signals short-term momentum. The RSI(14) at 65.2 edges toward overbought territory but remains neutral, suggesting room for further upside before potential consolidation. Volume surged to 4.04M shares, significantly above the 20-day average of 2.37M, confirming strong participation in the rally. TMO’s proximity to its 52-week high ($705.78) indicates limited overhead resistance, while the substantial distance from the low ($457.29) underscores robust support levels. The stock’s position near record highs reflects sustained bullish sentiment, though overbought RSI and elevated volume warrant caution for near-term pullbacks.